文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

玻璃体切除术、视网膜下组织型纤溶酶原激活剂与玻璃体腔气体注射治疗渗出性年龄相关性黄斑变性继发黄斑下出血(TIGER):一项3期、泛欧洲、两组、非商业性、活性对照、观察者设盲、优效性、随机对照手术试验的研究方案

Vitrectomy, subretinal Tissue plasminogen activator and Intravitreal Gas for submacular haemorrhage secondary to Exudative Age-Related macular degeneration (TIGER): study protocol for a phase 3, pan-European, two-group, non-commercial, active-control, observer-masked, superiority, randomised controlled surgical trial.
PubMed 文献 · Trials · 2022-01-31

TIGER是一项3期、泛欧洲、两组、活性对照、观察者设盲、优效性、随机对照手术试验,计划纳入210例因初治或经治新生血管性AMD(含息肉状脉络膜血管病变和视网膜血管瘤样增生)导致黄斑下出血(SMH)且持续时间不超过15天的患者,按1:1随机接受玻璃体切除术联合视网膜下TPA(最多25 μg/0.25 ml)、玻璃体腔20%六氟化硫气体及玻璃体腔阿柏西普,或仅玻璃体腔阿柏西普单药治疗。主要疗效终点为第12个月研究眼最佳矫正视力(BCVA)较基线提高≥10个ETDRS字母的受试者比例。

要点

  • TIGER为3期优效性随机对照手术试验,比较SMH手术联合方案与阿柏西普单药治疗。
  • 计划纳入210例,1:1随机,主要终点为第12个月BCVA提高≥10个ETDRS字母的比例。
  • 两组均接受阿柏西普2 mg每月1次共3次,之后每2个月1次至第12个月。

核心结论

  • SMH的最佳管理方式尚不明确;TIGER旨在确定相对于阿柏西普单药治疗,SMH手术的获益是否大于风险。

研究设计与样本

  • TIGER是一项3期、泛欧洲、两组、活性对照、观察者设盲、优效性、随机对照手术试验,计划纳入210例受试者。
  • 纳入标准为因初治或经治新生血管性AMD(包括特发性息肉状脉络膜血管病变和视网膜血管瘤样增生)导致黄斑下出血、累及中心凹且持续时间不超过15天。
  • 受试者按1:1比例随机接受玻璃体切除术、视网膜下注射标签外TPA最多25 μg/0.25 ml、玻璃体腔注射20%六氟化硫气体及玻璃体腔注射阿柏西普,或仅玻璃体腔注射阿柏西普单药治疗。

主要发现

  • 主要疗效终点为第12个月研究眼BCVA较基线提高≥10个ETDRS字母的受试者比例。
  • 次要疗效终点(除非另有说明,为第6个月和第12个月)包括第6个月BCVA提高≥10个ETDRS字母的受试者比例、平均ETDRS BCVA、Radner最大阅读速度、美国国家眼科研究所25项视觉功能问卷综合评分、EQ-5D-5L联合视力附加项评分、Short Warwick and Edinburgh心理健康评分、Humphrey视野分析仪上的暗点大小,以及通过独立阅读中心多模态图像分析评估的视网膜下纤维化和/或萎缩的存在与否及纤维化/萎缩面积(仅第12个月)。
  • 关键安全性结局为不良事件、严重不良事件和重要医学事件,使用监管活动医学词典首选术语进行编码。

关键数值与推荐

  • 两组均接受阿柏西普2 mg每月1次共3次,之后每2个月1次至第12个月。
  • 视网膜下TPA剂量为标签外使用,最多25 μg/0.25 ml。
  • 玻璃体腔气体为20%六氟化硫。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Neovascular (wet) age-related macular degeneration (AMD) can be associated with large submacular haemorrhage (SMH). The natural history of SMH is very poor, with typically marked and permanent loss of central vision in the affected eye. Practice surveys indicate varied management approaches including observation, intravitreal anti-vascular endothelial growth factor therapy, intravitreal gas to pneumatically displace SMH, intravitreal alteplase (tissue plasminogen activator, TPA) to dissolve the clot, subretinal TPA via vitrectomy, and varying combinations thereof. No large, published, randomised controlled trials have compared these management options. METHODS: TIGER is a phase 3, pan-European, two-group, active-control, observer-masked, superiority, randomised controlled surgical trial. Eligible participants have large, fovea-involving SMH of no more than 15 days duration due to treatment-naïve or previously treated neovascular AMD, including idiopathic polypoidal choroidal vasculopathy and retinal angiomatous proliferation. A total of 210 participants are randomised in a 1:1 ratio to pars plana vitrectomy, off-label subretinal TPA up to 25 μg in 0.25 ml, intravitreal 20% sulfahexafluoride gas and intravitreal aflibercept, or intravitreal aflibercept monotherapy. Aflibercept 2 mg is administered to both groups monthly for 3 doses, then 2-monthly to month 12. The primary efficacy outcome is the proportion of participants with best-corrected visual acuity (BCVA) gain of ≥ 10 Early Treatment Diabetic Retinopathy (ETDRS) letters in the study eye at month 12. Secondary efficacy outcomes (at 6 and 12 months unless noted otherwise) are proportion of participants with a BCVA gain of ≥ 10 ETDRS letters at 6 months, mean ETDRS BCVA, Radner maximum reading speed, National Eye Institute 25-item Visual Function Questionnaire composite score, EQ-5D-5L with vision bolt-on score, Short Warwick and Edinburgh Mental Wellbeing score, scotoma size on Humphrey field analyser, and presence/absence of subfoveal fibrosis and/or atrophy and area of fibrosis/atrophy using independent reading centre multimodal image analysis (12 months only). Key safety outcomes are adverse events, serious adverse events, and important medical events, coded using the Medical Dictionary for Regulatory Activities Preferred Terms. DISCUSSION: The best management of SMH is unknown. TIGER aims to establish if the benefits of SMH surgery outweigh the risks, relative to aflibercept monotherapy. TRIAL REGISTRATION: ClinicalTrials.gov NCT04663750 ; EudraCT: 2020-004917-10.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Jackson TL, Bunce C, Desai R, et al. Vitrectomy, subretinal Tissue plasminogen activator and Intravitreal Gas for submacular haemorrhage secondary to Exudative Age-Related macular degeneration (TIGER): study protocol for a phase 3, pan-European, two-group, non-commercial, active-control, observer-masked, superiority, randomised controlled surgical trial. Trials. 2022. PMID: 35101110. doi:10.1186/s13063-021-05966-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。